Recent Updates
Recently added Catalysts
MESO Neutral Sentiment

Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change 5,451,434 ordinary shares (including 41,162 ADS - each ADS represents

Key Takeaway: The article reports on a Change of Director's Interest Notice issued by Mesoblast Limited regarding Dr. Eric Rose. As of December 13, 2024, Dr. Rose has increased his holdings to 5,451,434 ordinary shares, including 41,162 American Depositary Shares (ADSs). This change includes a significant acquisition of 5,039,814 ordinary shares, which was valued at approximately A$1.5 million. The acquisition occurred through a share placement approved by shareholders at the upcoming 2024 AGM.
Price reaction · baseline $14.63 (2024-12-20 close) · clean, no other MESO news in the window
day 0 close
+17.8%
day 1
+16.3%
day 3 · peak
+19.8%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+91%
120-day peak, hindsight
Typical move
31.6%
average across 4 past catalysts
Lead asset
Prochymal
Phase 2 · Pulmonary Disease, Chronic Obstructive

Full Press Release Details

Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Mesoblast Limited ABN 68 109 431 870 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Dr Eric Rose Date of last notice 10 May 2024 Part 1 - Change of director's relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part. Direct or indirect interest Direct interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Eric Rose Date of change 13 December 2024 No. of securities held prior to change 411,620 ordinary shares (held as 41,162 American Depositary Shares "ADS") 4,330,765 options Class Ordinary shares Number acquired 5,039,814 ordinary shares Number disposed Not applicable Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation A$1.5 million Exhibit 99.1
Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change 5,451,434 ordinary shares (including 41,162 ADS - each ADS represents 10 ordinary shares) 4,330,765 options Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Share placement with approval by shareholders at the 2024 AGM Part 2 - Change of director's interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part. Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable Date of change Not applicable No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Not applicable Interest acquired Not applicable Interest disposed Not applicable Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Not applicable Interest after change Not applicable Part 3 - +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? Not applicable
Appendix 3Y Change of Director's Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 If prior written clearance was provided, on what date was this provided? Not applicable

Frequently Asked Questions

What entity is mentioned in the director's interest notice?

The entity is Mesoblast Limited, ABN 68 109 431 870.

Who is the director involved in the interest changes?

The director is Dr. Eric Rose.

What is the date of the last notice?

The last notice was dated 10 May 2024.

How many ordinary shares does Dr. Rose hold after the change?

Dr. Rose holds 5,451,434 ordinary shares after the change.

What was the nature of the change in interests?

The change was due to a share placement approved at the 2024 AGM.

Last updated: Dec 23, 2024